Prescription Vision London says on their website: “Research shows that chronic eye rubbing stands out as one of the most ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Keratoconus is a progressive eye condition that affects the shape and clarity of the cornea, often beginning in the teenage years or early adulthood. As the cornea thins and bulges into a cone-like ...

Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript October 30, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator ...

Earnings call Glaukos reported Q3 2025 net sales of $133.5M, up 38% YoY, led by iDose TR sales of $40M. FY25 revenue guidance was raised to $490–$495M (from $480–$486M), and preliminary FY26 guidance ...

The FDA has approved Epioxa HD 0.239% / Epioxa 0.177% (riboflavin 5'-phosphate ophthalmic solution) for epithelium-on corneal collagen cross-linking to treat keratoconus in adults and children aged 13 ...

ALISO VIEJO, Calif. - Glaukos Corporation (NYSE:GKOS), a $5 billion medical technology company with a strong financial health score according to InvestingPro, has received U.S. Food and Drug ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...